Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 24.48 |
|---|---|
| High | 25.95 |
| Low | 23.97 |
| Bid | 24.40 |
| Offer | 25.88 |
| Previous close | 21.14 |
| Average volume | 6.80m |
|---|---|
| Shares outstanding | 695.49m |
| Free float | 499.14m |
| P/E (TTM) | -- |
| Market cap | 14.70bn USD |
| EPS (TTM) | -1.00 USD |
Data delayed at least 15 minutes, as of Feb 06 2026 21:00 GMT.
More ▼
- Priovant Announces Positive Phase 2 Results for Brepocitinib in Cutaneous Sarcoidosis (CS)
- Roivant Announces Positive Phase 2 Results for Brepocitinib in Cutaneous Sarcoidosis (CS) and Reports Financial Results for the Third Quarter Ended December 31, 2025
- Roivant to Report Financial Results for the Third Quarter Ended December 31, 2025, and Provide Business Update on Friday, February 6, 2026
- Roivant Highlights Continued Pipeline Progress and Outlook for Company’s Next Phase of Growth at 2025 Investor Day
- Roivant Reports Financial Results for the Second Quarter Ended September 30, 2025, and Provides Business Update
- Roivant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, 2025
- Roivant and Priovant Announce Positive Phase 3 VALOR Study Results for Brepocitinib in 52-Week Placebo-Controlled Trial in Dermatomyositis (DM)
- Roivant Named on Fortune Media and Great Place To Work’s 2025 Best Workplaces in BioPharma List
- Roivant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients
- Roivant Reports Financial Results for the First Quarter Ended June 30, 2025, and Provides Business Update
More ▼
